Protalix Biotherapeutics, Inc.(NYSE Amex Equities : PLX)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Services » Servicestothe Health Industry
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CERN | Cerner Corporation | -0.47% | 56.69 | 7.6% | $122.41m | |
| DGX | Quest Diagnostics Incorporated | -0.89% | 88.45 | 4.3% | $121.04m | |
| LH | Laboratory Corporation of America Holdings | -0.91% | 152.92 | 2.3% | $96.35m | |
| SRCL | Stericycle, Inc. | 2.44% | 51.72 | 6.3% | $63.65m | |
| HCSG | Healthcare Services Group, Inc. | 1.15% | 32.51 | 6.7% | $52.57m | |
| OMCL | Omnicell, Inc. | -0.28% | 79.75 | 10.6% | $29.56m | |
| MDRX | Allscripts Healthcare Solutions, Inc. | 0.10% | 9.91 | 9.9% | $25.56m | |
| HMSY | HMS Holdings Corp. | 0.07% | 30.90 | 1.9% | $22.36m | |
| CPSI | Computer Programs and Systems, Inc. | 0.50% | 29.99 | 32.9% | $4.09m | |
| HSTM | HealthStream, Inc. | 0.50% | 27.99 | 6.7% | $3.70m | |
| PMD | Psychemedics Corporation | -4.53% | 14.55 | 0.7% | $0.49m | |
| PLX | Protalix Biotherapeutics, Inc. | -10.65% | 0.41 | 5.8% | $0.23m | |
| IDXG | Interpace Diagnostics Group, Inc. | -0.98% | 0.84 | 3.3% | $0.22m | |
| BASI | Bioanalytical Systems, Inc. | 0.00% | 2.00 | 0.3% | $0.05m | |
| STRM | Streamline Health Solutions, Inc. | -8.70% | 1.05 | 0.3% | $0.01m |
Company Profile
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.